The CCDC62 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the human CCDC62 gene. This product provides a genetically heterogeneous pool of HAP1 cells carrying targeted disruptions in CCDC62, generated via CRISPR/Cas9-mediated gene disruption. The polyclonal format retains the diversity of editing outcomes, enabling robust functional analysis without clonal selection.
The HAP1 cell line is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia (CML) line. Its near-haploid karyotype makes it a powerful tool for haploid genetic screens, functional genomics, and drug discovery. HAP1 cells express many features of the parental CML line and are widely used to study hematological malignancies and other cancer processes.
CCDC62 encodes a coiled-coil domain-containing protein that functions as a molecular scaffold, mediating protein-protein interactions critical for flagellar assembly during spermatogenesis. The protein interacts with flagellar and centrosomal partners including SPAG6, SPAG16, and CFAP family proteins, and is implicated in cytoskeletal remodeling. In cancer, ectopic expression of CCDC62 may contribute to oncogenic signaling pathways and altered cell proliferation and migration. Upstream regulators include SOX family transcription factors and retinoic acid signaling, while its downstream network involves components of the axonemal dynein complex, such as CFAP43, CFAP44, and AKAP family members. Thus, CCDC62 sits at the nexus of spermatogenesis-associated and cytoskeletal signaling pathways.
The HAP1 near-haploid background provides a unique advantage for studying CCDC62 function, as it allows straightforward genetic manipulation and screening without the complications of diploid gene redundancy. Disruption of CCDC62 in this model is particularly relevant for investigating the roles of cancer/testis antigens in leukemia and solid tumors, given the CML origin of the host cell line. This knockout model enables dissection of CCDC62-dependent phenotypes in cell growth, morphology, and signaling within a haploid context, facilitating high-throughput screens.
Researchers can employ these polyclonal knockout cells in a variety of assays, including immunoblotting, RT-qPCR, and Sanger sequencing for knockout validation, as well as cell proliferation assays (MTS/XTT) and immunofluorescence microscopy to assess phenotypic changes. Co-immunoprecipitation and RNA-seq analyses can map interaction partners and transcriptomic alterations, while flow cytometry permits cell cycle and functional analyses. The polyclonal population is particularly suited for pooled functional screens and drug sensitivity experiments. For further details, please contact Ascent Research.
